Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (381)
- Scheduling (national classification system) (178)
- Safety monitoring and information (33)
- COVID-19 (11)
- Manufacturing (11)
- Advertising (9)
- Clinical trials (8)
- Medicinal cannabis hub (6)
- Compliance and enforcement (5)
- Fees and payments (5)
- Sunscreens (5)
- Shortages and supply disruptions (4)
- Legislation (3)
- Breast implant hub (1)
- Import and export (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
777 result(s) found, displaying 151 to 175
-
Meeting statementsRead key points of discussion from the meeting 13 of the Medical Devices Consumer Working Group (MDCWG).
-
Meeting statementsRead the meeting statement from 8 February 2024 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsRead the meeting statement from 7 December 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Meeting statementsRead the meeting statement from 12 October 2023 meeting of the Advisory Committee on Medical Devices (ACMD).
-
Corporate reportsAn overview of the Medicines Repurposing Program's purpose and history.
-
Corporate reportsThis guide applies to the manufacture of medicines, active pharmaceutical ingredients and sunscreens, unless exempt under provisions in the Therapeutic Goods Act 1989.
-
Corporate reportsThis publication outlines our plan to transition to a paperless model for Special Access Scheme (SAS) and Authorised Prescriber (AP) submissions. From 1 July 2024 we will only accept submissions via the SAS/AP Online System.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 20 April 2023
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 13 July 2023
-
Meeting statementsAdvisory Committee on Complementary Medicines meeting statement for 9 November 2023
-
Scheduling decisions (final)Final decision on proposed amendments to the Poisons Standard relating to palovarotene
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Corporate reportsThis report provides information about our regulatory performance from 1 July 2022 to 30 June 2023.
-
Scheduling decisions (final)Read our notice of final decision to amend (or not amend) the current Poisons Standard in relation to bisacodyl, olopatadine and ibotenic acid.
-
Scheduling submissionsFind out about the public submissions on interim decisions for scheduling matters referred to the ACMS #42 and Joint ACMS-ACCS #34 meetings held in June 2023.
-
Meeting statementsRead key points of discussion from the meeting 12 of the Medical Devices Consumer Working Group (MDCWG).
-
Corporate reportsWe survey our stakeholders each year to help evaluate our performance and identify ways of improving.
-
Corporate reportsRead our 2023 stakeholder survey report, which aims to improve the way we work with our stakeholders.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsRead our Communique from the 5th meeting of the Women's Health Products Working Group (WHPWG), 30 October 2023.
-
Corporate reportsMedical Devices Safety Update (MDSU) provides practical advice and information about medical device safety.
-
Corporate reportsThe strategy outlines the approach we will use to identify, engage with, and educate stakeholders about regulatory requirements and our compliance outcomes.